Private Placement

A $25M deal for CleanPlanet reveals how Hardware-as-a-Service is making industrial sustainability profitable, slashing costs and carbon footprints on the factory floor.

Lithium Americas secures crucial financing for its Nevada mega-project, a move to navigate peak construction costs and reinforce its role in U.S. EV independence.

With a massive C$150M financing, Snowline Gold isn't just funding a mine; it's underwriting a new gold district in a high-stakes, supply-constrained market.

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

A private placement gives Africa Energy Corp. a vital cash injection for its South African gas project, but also tightens HCI's control to 42.5%.

Aeternum Health is no more. Reborn as a critical minerals supplier and led by a proven team, it's betting $4 million on a Nigerian mine to tackle US supply chain risk.

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

With its new CFO I, Star Mountain provides a rated, structured entry into U.S. lower middle-market lending, meeting growing institutional demand for safer yields.

IIP's Q2 results show a REIT in transition. While actively managing tenant defaults in its core cannabis portfolio, a major $270M bet on life sciences begins to pay off.

Ichor Holdings posts impressive Q2 growth, signaling a wider industry rebound. A $200M capital raise and disciplined strategy position it for the next tech supercycle.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

As Eastern Platinum repeatedly turns to an insider for cash, it uses a regulatory loophole to avoid shareholder votes. Is this savvy survival or a governance red flag?

WeTouch's leadership is injecting $38.8M into their own company. It's more than a financial move; it's a high-stakes pivot from touchscreens to robotics.

MetLife Investment Management's latest fund isn't just another capital raise; it's a masterclass in strategic portfolio optimization via the secondary market.

Autolus Therapeutics reports a 100% year-over-year sales jump and a stunning gross margin reversal, securing a $250M credit facility to fund its next big move.

NewcelX secured a small but vital $1.4M financing at a 20% premium. It's a bold vote of confidence, but is it enough to outrun a 'going concern' warning?

Blue Sea Capital's oversubscribed deal for One Physics isn't just a transaction; it's a playbook for a new era in private equity and healthcare services.

ReadyCap Lending's latest capital raise isn't just a transaction; it's a calculated move to fuel small business growth while navigating a complex corporate restructuring.

The community bank's Q2 profit turnaround isn't just a number—it's a blueprint for navigating a tough market through smart growth and pristine credit quality.

With a newly upsized $5M financing, Relief AI is merging with a public shell to launch 'NAIA Relief Inc.' on the TSXV, betting on its AI human coach.